Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
University of San Francisco, San Francisco, California Vitreo Retinal Associates, Gainesville, Florida Bascom Palmer Eye Institute, Miami, Florida Wilmer Eye Institute at John Hopkins, Baltimore, Maryland Massachusetts Eye and Ear, Boston, Massachusetts University of Michigan Kellogg Eye Center, Ann Arbor, Michigan Cincinnati Eye Institute, Cincinnati, Ohio Casey Eye Institute OHSU, Portland, Oregon Retina Foundation of the Southwest, Dallas, Texas Retina Consultants of Texas, Houston, Texas